BR1100680A - Antagonistas tricìclos de receptores de 5-ht3 - Google Patents

Antagonistas tricìclos de receptores de 5-ht3

Info

Publication number
BR1100680A
BR1100680A BR1100680-3A BR1100680A BR1100680A BR 1100680 A BR1100680 A BR 1100680A BR 1100680 A BR1100680 A BR 1100680A BR 1100680 A BR1100680 A BR 1100680A
Authority
BR
Brazil
Prior art keywords
alkyl
amino
alkoxy
halogen
optionally substituted
Prior art date
Application number
BR1100680-3A
Other languages
English (en)
Inventor
Jacob Berger
Robin Douglas Clark
Richard M Elgen
William L Smith
Klaus K Weinhardt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23755479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR1100680(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR1100680A publication Critical patent/BR1100680A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Saccharide Compounds (AREA)
BR1100680-3A 1989-11-28 1997-05-08 Antagonistas tricìclos de receptores de 5-ht3 BR1100680A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44208289A 1989-11-28 1989-11-28

Publications (1)

Publication Number Publication Date
BR1100680A true BR1100680A (pt) 2000-02-08

Family

ID=23755479

Family Applications (1)

Application Number Title Priority Date Filing Date
BR1100680-3A BR1100680A (pt) 1989-11-28 1997-05-08 Antagonistas tricìclos de receptores de 5-ht3

Country Status (23)

Country Link
US (1) US5202333A (pt)
EP (1) EP0430190B1 (pt)
JP (1) JPH0662607B2 (pt)
KR (1) KR970007917B1 (pt)
AT (1) ATE124698T1 (pt)
AU (1) AU642178B2 (pt)
BR (1) BR1100680A (pt)
CA (1) CA2030718C (pt)
DE (2) DE69020694T2 (pt)
DK (1) DK0430190T3 (pt)
ES (1) ES2075121T3 (pt)
FI (1) FI98367C (pt)
HK (1) HK36097A (pt)
HU (1) HU218654B (pt)
IE (1) IE68434B1 (pt)
IL (2) IL110622A (pt)
LU (1) LU91162I2 (pt)
NL (1) NL300194I2 (pt)
NO (2) NO175309C (pt)
NZ (1) NZ236225A (pt)
PL (3) PL166267B1 (pt)
PT (1) PT96001B (pt)
ZA (1) ZA909529B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI98367C (fi) * 1989-11-28 1997-06-10 Syntex Inc Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP0679088B1 (en) * 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
DK0748213T3 (da) * 1994-03-07 2004-08-02 Nektar Therapeutics Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
US5567818A (en) * 1994-07-08 1996-10-22 Syntex (U.S.A.) Inc. Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
US5510486A (en) * 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US5492914A (en) * 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5723103A (en) * 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
WO2000048581A2 (en) * 1999-02-18 2000-08-24 Novartis Ag Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
AU2001261606A1 (en) * 2000-05-18 2001-11-26 Glaxo Group Limited Method for treating functional dyspepsia
MXPA04005865A (es) 2001-12-19 2004-09-13 Nektar Therapeutics Suministro de aminoglucosidos a los pulmones.
MXPA04007083A (es) 2002-02-20 2004-10-29 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
CN100336508C (zh) * 2005-02-23 2007-09-12 重庆医药工业研究院有限责任公司 一种稳定的帕洛诺司琼注射液
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US8614225B2 (en) * 2006-08-30 2013-12-24 Dr. Reddy's Laboratories Limited Process for the purification of palonosetron or its salt
WO2008051539A2 (en) * 2006-10-23 2008-05-02 Sicor Inc. Processes for preparing palonosetron salts
UA97653C2 (ru) * 2006-10-24 2012-03-12 Хелсинн Хелткер С.А. Мягкие капсулы, содержащие палоносетрона гидрохлорид, которые имеют улучшенную стабильность и биологическую доступность
EP2099298A4 (en) * 2006-12-07 2010-01-06 Helsinn Healthcare Sa CRYSTALLINE AND AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE
WO2008146283A2 (en) * 2007-05-29 2008-12-04 Chemagis Ltd. Novel palonosetron salts and processes for preparation and purification thereof
US20090227623A1 (en) * 2007-09-15 2009-09-10 Protia, Llc Deuterium-enriched palosetron
CN101157691B (zh) * 2007-10-18 2011-01-12 杭州九源基因工程有限公司 一种盐酸帕洛诺司琼的生产工艺
AR069625A1 (es) * 2007-12-13 2010-02-03 Glenmark Generics Ltd Base libre de palonosetron y procedimiento para su preparacion
WO2009087643A1 (en) * 2008-01-11 2009-07-16 Natco Pharma Limited Novel crystalline forms of palonosetron hydrochloride
WO2009136405A1 (en) * 2008-05-05 2009-11-12 Natco Pharma Limited High purity palonosetron base and its solid state characteristics
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
US20100099701A1 (en) * 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
EP2364312A4 (en) * 2008-11-11 2012-05-02 Reddys Lab Ltd Dr SYNTHESIS OF CRYSTALLINE PALONOSETRON CHLORHYDRATE
EP2364138A2 (en) * 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
JP2012512163A (ja) * 2008-12-11 2012-05-31 エーピー ファーマ， インコーポレイテッド ポリオルトエステルおよびそれらの製剤の安定性を高めるための方法
CN101851233B (zh) * 2009-04-03 2013-03-06 四川滇虹医药开发有限公司 盐酸帕洛诺司琼和其前体化合物及制备
CN101849904A (zh) * 2009-04-03 2010-10-06 南京长澳医药科技有限公司 一种帕洛诺司琼注射液及其制备方法
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
JP5955767B2 (ja) 2009-05-20 2016-07-20 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 損傷性前庭障害の処置における使用のためのセロトニン５−ｈｔ３受容体拮抗薬
ES2432618T3 (es) 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
US20120267533A1 (en) 2009-06-30 2012-10-25 Ranbaxy Laboratories Limited Processes for the preparation of form i and form ii of palonosetron hydrochloride
WO2011008572A2 (en) 2009-07-14 2011-01-20 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
WO2011013095A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Processes for the preparation of palonosetron
JP2013510843A (ja) * 2009-11-13 2013-03-28 ヘルシン ヘルスケア ソシエテ アノニム パロノセトロン代謝産物先行出願との関連本出願は２００９年１１月１３日に出願された米国仮出願第６１／２６０，９１６号の優先権を主張する。
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
ES2494015T3 (es) 2009-11-18 2014-09-12 Helsinn Healthcare Sa Composiciones para tratar nauseas y vómitos de origen central
DK2744497T3 (en) 2011-10-18 2016-08-01 Helsinn Healthcare Sa THERAPEUTIC COMBINATION OF netupitant AND palonosetron
CN102688185B (zh) * 2012-06-01 2013-07-10 齐鲁制药(海南)有限公司 一种稳定的帕洛诺司琼注射液及其制备方法
US9877959B2 (en) 2013-12-23 2018-01-30 Samyang Biopharmaceuticals Corporation Pharmaceutical composition containing palonosetron
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
EP3672964A4 (en) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3341528A (en) * 1963-11-07 1967-09-12 Warner Lambert Pharmaceutical Substituted benzoquinolines
US3896132A (en) * 1969-08-19 1975-07-22 Hoffmann La Roche Process for preparing 1,2,3,8,9,9a-hexahydro-5,6-dialkoxy-1-alkyl-benzo(d,e)quinolin-7-ore compounds
US4309543A (en) * 1980-03-17 1982-01-05 Dynapol Process for preparing cyclic amides
EP0093488A3 (en) * 1982-03-18 1984-05-23 Beecham Group Plc Nortropyl benzopyrrolinone compounds, process for their preparation and pharmaceutical compositions containing them
US4571396A (en) * 1984-04-16 1986-02-18 Warner-Lambert Company Antibacterial agents
WO1988004292A1 (en) * 1986-12-11 1988-06-16 The Upjohn Company Antipsychotic amino-polyhydro-benz-(iso)quinolines and intermediates
EP0315390B1 (en) * 1987-11-04 1994-07-20 Beecham Group Plc Novel 4-oxobenzotriazines and 4-oxoquinazolines
FI98367C (fi) * 1989-11-28 1997-06-10 Syntex Inc Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi
AU7618991A (en) * 1990-05-14 1991-11-14 Syntex (U.S.A.) Inc. Novel tricyclic compounds
US5189041A (en) * 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists

Also Published As

Publication number Publication date
HUT56368A (en) 1991-08-28
NL300194I1 (nl) 2005-07-01
JPH0662607B2 (ja) 1994-08-17
NO2005023I1 (no) 2005-10-03
NL300194I2 (nl) 2005-07-01
FI98367C (fi) 1997-06-10
NO175309C (no) 1994-09-28
PL166277B1 (pl) 1995-04-28
FI98367B (fi) 1997-02-28
ZA909529B (en) 1992-08-26
PT96001A (pt) 1991-09-30
EP0430190B1 (en) 1995-07-05
NO2005023I2 (no) 2009-10-05
EP0430190A2 (en) 1991-06-05
NZ236225A (en) 1992-09-25
EP0430190A3 (en) 1992-01-22
NO905120D0 (no) 1990-11-27
ES2075121T3 (es) 1995-10-01
NO905120L (no) 1991-05-29
KR910009699A (ko) 1991-06-28
CA2030718C (en) 1998-05-12
IE904269A1 (en) 1991-06-05
AU642178B2 (en) 1993-10-14
AU6696390A (en) 1991-06-06
IL96486A0 (en) 1991-08-16
NO175309B (no) 1994-06-20
IL110622A (en) 1995-03-30
DE122005000027I1 (de) 2005-08-04
HK36097A (en) 1997-03-27
FI905839A (fi) 1991-05-29
HU907660D0 (en) 1991-06-28
CA2030718A1 (en) 1991-05-29
JPH03176486A (ja) 1991-07-31
PL166272B1 (pl) 1995-04-28
ATE124698T1 (de) 1995-07-15
US5202333A (en) 1993-04-13
DE122005000027I2 (de) 2006-03-16
IL96486A (en) 1995-03-30
IE68434B1 (en) 1996-06-12
HU218654B (hu) 2000-10-28
PL287961A1 (en) 1991-12-02
FI905839A0 (fi) 1990-11-27
DE69020694D1 (de) 1995-08-10
LU91162I2 (fr) 2005-06-20
PL166267B1 (pl) 1995-04-28
DK0430190T3 (da) 1995-08-21
PT96001B (pt) 1998-01-30
KR970007917B1 (ko) 1997-05-17
DE69020694T2 (de) 1996-01-18

Similar Documents

Publication Publication Date Title
BR1100680A (pt) Antagonistas tricìclos de receptores de 5-ht3
KR900012911A (ko) 흥분성 아미노산 수용기 길항질 화합물
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
DE69706407D1 (de) META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
DE60023318D1 (de) Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
PT753301E (pt) Combinacao de um benzimidazole tendo actividade antagonista da angiotensina ii com um diuretico
EA199800794A1 (ru) Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
ID25477A (id) Turunan-turunan spiropiperidin
DE69402703D1 (de) 3-(INDOL-3-YL) PROPENSäURDERIVATE, DIE ALS NMDA- ANTAGONISTEN NÜTZLICH SIND
EA200500024A1 (ru) 1-фенилалкил-пиперазины
WO1997029077A1 (fr) Derives amides substitues
ES2057121T3 (es) Antagonistas de los receptores alfa-adrenergicos.

Legal Events

Date Code Title Description
AN Processing applications according to articles 230 and 231 of law 9279/96: notification of filing an application
HHFK Processing applications according to articles 230 and 231 of law 9.279/96: republication
MT Patent procedure suspended until requirement met - articles 230 and 231 of law 9279/96
FGAN Processing applications according to articles 230 and 231 of law 9.279/96: granting
NB Patent issued - articles 230 and 231 of law 9279/96